Numaferm

Numaferm is a German biotechnology company based in Düsseldorf that specializes in the recombinant production of peptides, proteins, and pepteins. Founded in 2017, the company utilizes proprietary technology platforms, including Numascreen for lead discovery and Numatech for scalable expression. These solutions enable the development and manufacturing of complex molecules, particularly those in the range of 30-500 amino acids, which are often difficult to produce using traditional chemical synthesis or standard recombinant methods. The company operates in accordance with ISO 9001:2015 standards and maintains a partner network of contract manufacturing organizations to facilitate scale-up and commercial production.

By providing efficient, sustainable, and cost-effective production processes, Numaferm supports partners in the pharmaceutical, biotech, cosmetic, and agricultural industries. The company offers end-to-end services, ranging from initial lead discovery and cell line development to the implementation of analytics and GMP-compliant material supply. Numaferm has demonstrated its capabilities through numerous successful projects and strategic collaborations, such as a licensing agreement with Zoetis for the development of veterinary therapeutics. Their platform technology aims to remove cost-related barriers to innovation, helping customers accelerate the development of safer and more effective products.